Korro Bio Inc
KRRO33.840USD
+1.270+3.90%
收盤 11/07, 16:00（美東）報價延遲15分鐘
317.79M總市值
虧損本益比TTM
關於 Korro Bio Inc 公司
Korro Bio, Inc. 是一家生物製藥公司。該公司發現、開發和商業化基於編輯核糖核酸 (RNA) 的基因藥物，從而能夠治療罕見和高度流行的疾病。該公司正在生成一系列差異化項目，旨在利用人體天然的 RNA 編輯過程來實現精確但短暫的單鹼基編輯。通過編輯 RNA 而不是 DNA，該公司正在擴大基因藥物的覆蓋範圍。其寡核苷酸促進的 RNA 編輯 (OPERA) 是 RNA 編輯的基礎平臺，旨在通過提供可以靶向特定 RNA 序列的寡核苷酸嚮導來編輯體內 RNA。該公司的首個開發候選藥物 KRRO-110 正在開發中，作爲 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的潛在治療方法，具有改變疾病並提供差異化治療選擇的潛力。
Korro Bio Inc簡介
公司代碼KRRO
公司名稱Korro Bio Inc
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
員工數量104
證券類型Ordinary Share
年結日Oct 03
公司地址One Kendall Square. Building 600-700
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02139
電話16174681999
網址https://www.korrobio.com/
公司代碼KRRO
上市日期Oct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Korro Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
收入明細
FY2025Q2
FY2025Q1
FY2024
暫無數據
地區USD
名稱
營收
佔比
United States
1.46M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8 小時前
更新時間: 8 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
持股股東
持股股東
佔比
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
其他
57.53%
股東類型
持股股東
佔比
Investment Advisor
30.67%
Hedge Fund
27.09%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.96%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
186
9.14M
97.37%
-1.25M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Atlas Venture
1.14M
12.11%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
639.22K
6.81%
-4.05K
-0.63%
Jun 30, 2025
Driehaus Capital Management, LLC
580.86K
6.19%
-1.59K
-0.27%
Jun 30, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
540.07K
5.75%
+19.18K
+3.68%
Jun 30, 2025
Cormorant Asset Management, LP
465.00K
4.95%
+84.70K
+22.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
423.16K
4.51%
+15.35K
+3.76%
Jun 30, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
386.74K
4.12%
+4.94K
+1.29%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0.07%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.07%
Avantis US Small Cap Equity ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
SPDR Portfolio MSCI Global Stock Market ETF
佔比0%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
公告日期
類型
比率
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
